The WISH Act probably isn’t going anywhere, but it’s interesting anyway . . .
Forbes post, “The FDA Approves The Alzheimer’s Drug Aducanumab — And Reminds Us Of The Herculean Task Of Medicare Reform”
How willing are we to say “no” to more spending and more questionably-effective drugs?